Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions

Campaign highlights unmet needs in myeloma and new science like CELMoD research that is giving patients and their loved ones hope

Bristol Myers Squibb (NYSE:BMY) today announced the launch of "Investigating Myeloma,"a multiple myeloma awareness campaign, in partnership with award-winning actor, director, producer and advocate Mariska Hargitay. This campaign spotlights the importance of ongoing scientific investigation in multiple myeloma, including an approach called CELMoD research led by BMS, defined as cereblon E3 ligase modulation. CELMoD research focuses on engaging key proteins involved in the disease for breakdown by the cell's own protein removal system to stimulate the immune system and enhance cancer cell killing. For Mariska, this campaign is deeply personal as she reflects on how research has evolved 20 years after her father, Mickey Hargitay, passed away from the disease.